
CLAIMS

1. A compound of formula (XI):



(XI)

;

wherein:

V is -O-, -N(CH_3)- or -CH_2- and Y is -N(CH_3)- or -CH_2-;

or V is -N(CH_3)- or -CH_2- and Y is -O-, -N(CH_3)- or -CH_2-; and

R^{14} is hydrogen, [5-(trifluoromethyl)furan-2-yl]methyl, pyridin-2-ylmethyl, [3-(trifluoromethyl)pyridin-2-yl]methyl or (2*R*)-tetrahydrofuran-2-ylmethyl; provided that when V is –O-, Y is not –CH_2-;

or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Claim 1, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

3. The compound of Claim 1, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; for use in a method of treating pain in a mammal by the inhibition of ion flux through a voltage-dependent sodium channel in the mammal, wherein said compound, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; is for administering to the mammal in need thereof in a therapeutically effective amount.

4. The compound of Claim 1, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; for use in a method of decreasing ion flux through a voltage-dependent sodium channel in a cell in a mammal, wherein the method comprises contacting the cell with said compound , or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically

acceptable salt, solvate or prodrug thereof.

5. The compound of Claim 1, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; for use in a method of treating hypercholesterolemia, benign prostatic hyperplasia or pruritis in a mammal, wherein said compound, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; is for administering to the mammal in need thereof in a therapeutically effective amount.

6. Use of the compound of Claim 1, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; in the preparation of a medicament for treating pain in a mammal by the inhibition of ion flux through a voltage-dependent sodium channel in the mammal.

7. Use of the compound of Claim 1, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; in the preparation of a composition for decreasing ion flux through a voltage-dependent sodium channel in a cell in a mammal, wherein said compound, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof is for contacting the cell.

8. Use of the compound of Claim 1, or a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof; in the preparation of a medicament for treating hypercholesterolemia, benign prostatic hyperplasia or pruritis in a mammal.

9. The compound of Claim 1 wherein both V and Y are each $-CH_2-$.

10. The compound of Claim 9 selected from:
1-(diphenylmethyl)-5',6',7',8'-tetrahydrospiro[indole-3,3'-naphtho[2,3-*b*]furan]-2(1*H*)-one;
5',6',7',8'-tetrahydrospiro[indole-3,3'-naphtho[2,3-*b*]furan]-2(1*H*)-one; or
1-[(2*R*)-tetrahydrofuran-2-ylmethyl]-5',6',7',8'-tetrahydrospiro[indole-3,3'-naphtho[2,3-*b*]furan]-2(1*H*)-one.

11. The compound of Claim 1 wherein V is -O- and Y is -N(CH_3)-.

12. The compound of Claim 11 selected from:
1-methyl-1'-{[5-(trifluoromethyl)furan-2-yl]methyl}-2,3-dihydro-1*H*-spiro[furo[3,2-*g*][1,4]benzoxazine-8,3'-indol]-2'(1'*H*)-one;
1-methyl-1'-{[5-(trifluoromethyl)furan-2-yl]methyl}-2,3-dihydro-1*H*-spiro[furo[3,2-*g*][1,4]benzoxazine-8,3'-indol]-2'(1'*H*)-one hydrochloride;
1-methyl-1'-[(2*R*)-tetrahydrofuran-2-ylmethyl]-2,3-dihydro-1*H*-spiro[furo[3,2-*g*][1,4]benzoxazine-8,3'-indol]-2'(1'*H*)-one; or
1-methyl-1'-[(2*R*)-tetrahydrofuran-2-ylmethyl]-2,3-dihydro-1*H*-spiro[furo[3,2-*g*][1,4]benzoxazine-8,3'-indol]-2'(1'*H*)-one hydrochloride.

13. The compound of Claim 1 wherein V is -N(CH_3)- and Y is -O-.

14. The compound of Claim 13 which is 4-methyl-1'-[(2*R*)-tetrahydrofuran-2-ylmethyl]-3,4-dihydro-2*H*-spiro[furo[2,3-*g*][1,4]benzoxazine-8,3'-indol]-2'(1'*H*)-one.

15. The compound of Claim 1 wherein V is -CH_2- and Y is -O-.

16. The compound of Claim 15 selected from:
1'-(pyridin-2-ylmethyl)-7,8-dihydro-6*H*-spiro-[furo[2,3-*g*]chromene-3,3'-indol]-2'(1'*H*)-one; or
1'-{[3-(trifluoromethyl)pyridin-2-yl]methyl}-7,8-dihydro-6*H*-spiro[furo[2,3-*g*]chromene-3,3'-indol]-2'(1'*H*)-one.